ArticleCureus2025
Indolent Tumour of the Upper Lip: A Case of Lobulated Acinic Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A majority of minor salivary gland neoplasms are encountered more frequently on the upper lip when compared to lower lip lesions. Although upper lip tumours generally turn out to be benign adenomas in the form of monomorphic adenomas and pleomorphic adenomas in 90% of the cases, rarely, a few indolent masses turn out to be carcinomas. Here, we report a long standing indolent upper lip swelling, which turned out to be a low-grade acinic cell carcinoma (ACiCa). Minor salivary gland tumours (MSGTs), considered as benign clinically, should be evaluated histopathologically for the confirmation of diagnosis, especially to rule out malignancy. Detailed, systematic histopathological and immunohistochemical (IHC) assessment for validation and confirmatory diagnosis is imperative. An added evaluation for tumour outcome with affirmative markers (DOG1), proliferative markers (Ki67), add value in diagnosis and prognostication of this tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.